頁籤選單縮合
題名 | Effect of Alendronate and Teriparatide on Bone Mineral Density in Postmenopausal Women=阿崙膦酸鈉及特立帕肽對停經後婦女骨密度的影響 |
---|---|
作者 | 陳佩岑; 江清泉; 江鴻生; | 書刊名 | 臺灣復健醫學雜誌 |
卷期 | 40:3 2012.09[民101.09] |
頁次 | 頁135-140 |
分類號 | 417.224 |
關鍵詞 | 阿崙膦酸鈉; 特立帕肽; 骨密度; 骨質疏鬆症; Alendronate; Teriparatide; Bone mineral density; Osteoporosis; |
語文 | 英文(English) |
中文摘要 | 背景:雖然阿崙膦酸鈉及特立帕肽已被證實可以增加骨質密度,但目前在台灣,仍缺少相關的臨床研究報告。方法:本研究回溯從2008年至2010年,停經後婦女於台灣大學醫學院附設醫院有就診並且有骨質疏鬆或脊椎骨折診斷的門診病歷,納入使用阿崙膦酸鈉或特立帕肽連續六個月以上,而且在使用前後至少有一次腰椎骨質密度報告的病人。排除條件包含有次發性骨質疏鬆症(例如:長期服用類固醇者)、合併使用其他骨質疏鬆藥物者。分別紀錄用藥前,用藥6、12、18、30及42個月後的骨質密度(T score)。接著用配對t檢定比較兩組用藥前後骨密度的變化,並以混合模式分析年齡、用藥前骨密度和兩種藥物對骨密度增加的影響。結果:有37位病人接受阿崙膦酸鈉治療,25位病人接受特立帕肽治療,治療前的骨密度分別為為-3.18 ± 0.57 和 -3.30 ± 0.74。兩組病人在治療後骨密度皆有顯著增加(p=0.003 及p<0.001)。此外,混合模式分析發現兩組藥物對骨密度增加無顯著差異(p=0.74),年齡也不會影響藥物治療效果(p=0.20)。然而,用藥前骨密度較高的病人,對藥物治療的反應較好(p<0.001)。治療期間除零星腸胃和皮膚副作用,並無其他嚴重副作用產生。結論:阿崙膦酸鈉及特立帕肽皆可增加台灣停經後婦女的骨密度,兩者藥物效果不分軒輊。 |
英文摘要 | Background: Alendronate and teriparatide have been proved to benefit osteoporosis patients in some prospective studies. However, no data have been described about the clinical practice of these medications and their efficacy in Taiwanese people.Method: We reviewed the medical records of an outpatient clinic at National Taiwan University Hospital from 2008 to 2010, and collected data on the postmenopausal women diagnosed with osteoporosis or spinal compression fracture. Lumbar spinal bone mineral density (BMD) was recorded at baseline and at 6, 12, 18, 30, and 42 months after initiating therapy. We compared the patients' BMD before and after the treatment by paired t test. Mixed model for repeated BMD measurement was used to determine the effect of age, baseline BMD, and different medications on BMD.Results: Thirty-seven patients received alendronate and 25 received teriparatide. Mean T scores of BMD before treatment were -3.18 ± 0.57 and -3.30 ± 0.74 in the alendronate and teriparatide groups, respectively. After treatment, BMD increased significantly (alendronate group, p = 0.003; teriparatide group, p<0.001). The effects on BMD were comparable between the alendronate and teriparatide groups (p=0.74). Patients with higher baseline BMD responded to the medications significantly better than patients with lower baseline BMD. Adverse events were mild and few for both medications.Conclusions: Alendronate and teriparatide could increase lumbar spinal BMD in postmenopausal Taiwanese, with comparable efficacy between the two drugs. Patients with higher baseline BMD responded better to the medications. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。